Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway

Fig. 4

Upregulation of PD-L1 is related to EMT and invasion ability in cisplatin-resistant NSCLC. a. Higher expression of PD-L1 in cisplatin-resistant A549CisR and H157CisR cells determined by Western blot analysis. b Cisplatin treatment induces PD-L1 expression in NSCLC. A549P and H157P cells were treated with cisplatin (5 μM) for indicated time. Expression of PD-L1 was determined by Western blot. c ATM inhibitor (CP466722) downregulates PD-L1 expression. A549CisR and H157CisR cells were treated with inhibitor (CP466722) for 24 h. Expression of PD-L1 was determined by Western Blot. d ATM knockdown downregulates PD-L1 expression. A549CisR-siATM and H157CisR-siATM cells were generated Expression of PD-L1 was determined by Western Blot. e Anti-PD-L1 antibody inhibits phenotype of EMT in cisplatin-resistant cells. A549CisR and H157CisR cells were treated with PD-L1 neutralizing antibody for 24 h. Expressions of mRNA of EMT-related genes were determined by qPCR analysis. f Anti-PD-L1 antibody reduced cells invasion. A549P/A549CisR and H157P/H157CisR cells were placed in upper chamber of transwell plates (8 μM pore) and incubated with PD-L1 neutralizing antibody for 24 h. Invasive cells to lower chamber were counted under microscope 24 h after incubation. Quantitation analyses were shown on right panel. *p < 0.05, **p < 0.01, ***p < 0.001, compared with control treatment

Back to article page